FDA Issues Complete Response Letter to Janssen Biotech, Inc. for SIMPONI ... - PR Newswire (press release)

FDA Issues Complete Response Letter to Janssen Biotech, Inc. for SIMPONI ... PR Newswire (press release) In 2009, SIMPONI® received approvals in the United States, Europe and Canada for the treatment of moderately to severely active RA in combination with methotrexate, active psoriatic arthritis and active ankylosing spondylitis as a once-monthly ... and more »

BUYINS.NET: PFE, HCP, NU, IPGP, PCS, OZM Expected To Be Up Before Next ... - TMC Net

BUYINS.NET: PFE, HCP, NU, IPGP, PCS, OZM Expected To Be Up Before Next ... TMC Net ... polyarticular juvenile rheumatoid arthritis, psoriatic arthritis, plaque psoriasis, and ankylosing spondylitis; Lyrica for post-herpetic neuralgia, diabetic peripheral neuropathy, fibromyalgia, neuropathic pain, adjunctive treatment of epilepsy, ...

FDA Issues Complete Response Letter to Janssen Biotech, Inc. for SIMPONI ... - VAdvert Press Center (press release)

FDA Issues Complete Response Letter to Janssen Biotech, Inc. for SIMPONI ... VAdvert Press Center (press release) In 2009, SIMPONI® received approvals in the United States, Europe and Canada for the treatment of moderately to severely active RA in combination with methotrexate, active psoriatic arthritis and active ankylosing spondylitis as a once-monthly ... and more »

sanofi-aventis CEO Discusses Q2 2011 Results - Earnings Call Transcript - Seeking Alpha

sanofi-aventis CEO Discusses Q2 2011 Results - Earnings Call Transcript Seeking Alpha Not everything goes well, of course and sarilumab results in ankylosing spondylitis didn't work. And of course, we had the PALLAS study in Multaq, which was stopped due to side effects. So I think there is a lot of good progress on R&D. ... and more »